Uber and Moderna Collaborate to Raise Awareness and Increase Access to COVID-19 Vaccines
January 12 2021 - 8:00AM
Business Wire
Companies aim to build confidence in COVID-19 vaccines via
Uber’s global network of riders and drivers
Moderna (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, and Uber
Technologies, Inc. (NYSE: UBER), the world’s leading ridesharing
and delivery platform, today announced a collaboration to explore
ways to help support the uptake of COVID-19 vaccines.
Moderna and Uber will work together initially to provide
accessible, credible information on vaccine safety through Uber’s
in-app messaging. The two companies will also work with public
health and other organizations to identify additional opportunities
to support ongoing efforts to broaden access to COVID-19 vaccines.
Additional options being evaluated include incorporating ride
scheduling directly into the immunization appointment process, and
possibly integrating with vaccine providers’ systems to text
reminders and enable patients to book rides in advance of their
first or second immunization appointments.
“Used by millions of people every day, the Uber platform can
both help educate the public about vaccine safety and help
eliminate transportation barriers to vaccination. Together with
Moderna, we hope to do our part to help increase vaccination
awareness and adoption, and we look forward to exploring ways we
can help ensure everyone, especially in the hardest-hit communities
of color, has access to a vaccine,” said Uber CEO Dara
Khosrowshahi.
“As part of our commitment to help address COVID-19, Moderna
will be working with a coalition of partners to educate, build
trust around and increase awareness of the importance of
vaccination in those communities significantly impacted by the
pandemic. We look forward to combining our expertise with Uber’s
capabilities and platform to support this important effort,” said
Moderna CEO Stéphane Bancel.
In December, Uber committed 10 million free or discounted rides
to help ensure transportation is not a barrier to getting a
vaccine. Targeting communities hardest hit by the pandemic, Uber
partnered with the National Urban League, National Action Network
and the Morehouse School of Medicine. Uber will continue to build a
broad coalition of organizations committed to breaking down
transportation barriers in these communities.
The Moderna COVID-19 Vaccine has been authorized for emergency
use in the U.S. by the FDA for active immunization to prevent
coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18
years of age and older and has been authorized by Health Canada for
the immunization of Canadians 18 years of age and older under an
Interim Order. The Moderna COVID-19 Vaccine has also been granted a
Conditional Marketing Authorization by the European Commission,
based upon the recommendation of the European Medicines Agency,
which authorizes the COVID-19 Vaccine Moderna for active
immunization to prevent COVID-19 caused by SARS-CoV-2 virus in
individuals 18 years of age and older.
While initially targeting Uber users in the United States, the
companies anticipate expanding this partnership globally in the
coming months alongside ongoing immunization efforts.
About Uber
Uber’s mission is to create opportunity through movement. We
started in 2010 to solve a simple problem: how do you get access to
a ride at the touch of a button? More than 15 billion trips later,
we're building products to get people closer to where they want to
be. By changing how people, food, and things move through cities,
Uber is a platform that opens up the world to new
possibilities.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the
promising-but-still-unproven field of messenger RNA (mRNA), to an
enterprise with its first medicine having treated millions of
people, a diverse clinical portfolio of vaccines and therapeutics
across six modalities, a broad intellectual property portfolio in
areas including mRNA and lipid nanoparticle formulation, and an
integrated manufacturing plant that allows for both clinical and
commercial production at scale and at unprecedented speed. Moderna
maintains alliances with a broad range of domestic and overseas
government and commercial collaborators, which has allowed for the
pursuit of both groundbreaking science and rapid scaling of
manufacturing. Most recently, Moderna’s capabilities have come
together to allow the authorized use of one of the earliest and
most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 13 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Special Note Regarding Forward-looking
Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995,
including, without limitation, statements regarding collaborative
efforts between Uber and Moderna to facilitate vaccination with the
Moderna COVID-19 Vaccine and the provision of ridesharing services
to customers by Uber. While Uber and Moderna each believes the
forward-looking statements contained in this press release are
accurate, these forward-looking statements represent the companies’
beliefs only as of the date of this press release and there are a
number of risks and uncertainties that could cause actual events or
results to differ materially from those expressed or implied by
such forward-looking statements. Those risks and uncertainties
include, among other things, those risks listed under the heading
“Risk Factors” in Uber’s annual and quarterly reports filed with
the Securities and Exchange Commission (SEC) and available through
Uber’s website at www.uber.com and on the SEC’s website at
www.sec.gov, as well as those risks listed under the heading “Risk
Factors” in Moderna’s most recent quarterly report on Form 10-Q
filed with the SEC and in subsequent filings made by Moderna with
the SEC, which are available on Moderna’s website at
www.modernatx.com and on the SEC’s website at www.sec.gov. Except
as required by law, Uber and Moderna each disclaim any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new
information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210112005245/en/
Uber: press@uber.com
Moderna:
Colleen Hussey Director, Corporate Communications 617-335-1374
Colleen.Hussey@modernatx.com
Helen O’Gorman FTI Consulting 718-408-0800
Helen.OGorman@fticonsulting.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024